SCHEMBL4477463

SCHEMBL4477463

CC1(C)OB(c2ccc(C=O)c(Oc3ccccc3)c2)OC1(C)C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.49
GAA P10253 1/20 0.49
KMT2A Q03164 1/20 0.49
LIPG Q9Y5X9 7/20 0.44
LPL P06858 6/20 0.44
ALDH1A1 P00352 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
NPSR1 Q6W5P4 1/20 0.40
P4HB P07237 1/20 0.40
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA9 Q16790 1/20 0.39
TTR P02766 1/20 0.39
ERN1 O75460 1/20 0.36
SNCA P37840 1/20 0.36
DGAT1 O75907 1/20 0.36
CSF1R P07333 1/20 0.34
ROCK1 Q13464 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6865570 0.90 LMNA (0.49) LMNAGAAKMT2ALIPGLPL
SCHEMBL5801905 0.84 LMNA (0.57) LMNAGAAKMT2ALIPGLPL
SCHEMBL21994403 0.82 CA1 (0.43) LMNAGAAKMT2ALIPGLPL
SCHEMBL7513399 0.82 ALDH1A1 (0.50) LMNALIPGLPLALDH1A1P4HB
SCHEMBL1129141 0.80 TTR (0.48) LIPGLPLALDH1A1P4HBCA1
SCHEMBL1128900 0.79 TSHR (0.52) LMNAGAAKMT2ALIPGLPL
SCHEMBL20504766 0.78 LPL (0.41) LMNAGAALIPGLPLALDH1A1
SCHEMBL1129289 0.78 LIPG (0.49) LIPGLPLP4HBCA1CA2
SCHEMBL23783217 0.77 LPL (0.38) LIPGLPLALDH1A1P4HBCA1
SCHEMBL21497020 0.77 LPL (0.38) LIPGLPLALDH1A1P4HBCA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7629366-B2 Aminoalcohol derivatives FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2009-12-08 US disclosed
US-20060100252-A1 Aminoalcohol derivatives FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2006-05-11 US disclosed
US-7037938-B2 Aminoalcohol derivatives ASTELLAS PHARMA INC. (JP) 2006-05-02 US disclosed
US-20040006143-A1 For therapy of urinary incontinence FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-01-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060100252-A1 Aminoalcohol derivatives H1-0, CHRM2, CHRM1 LMNA 3590/4885GAA 3421/4885KMT2A 1218/4885
US-20040006143-A1 For therapy of urinary incontinence H1-0, HRH2, H1-2 LMNA 4565/4885GAA 3352/4885KMT2A 364/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.